Biodexa Pharmaceuticals
BDRX
5 hedge funds and large institutions have $87.3K invested in Biodexa Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 6 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
36% less capital invested
Capital invested by funds: $136K → $87.3K (-$48.3K)
50% less funds holding
Funds holding: 10 → 5 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$150K |
| 2 |
Morgan Stanley
New York
|
+$8.43K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$7.66K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$2.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$32K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$30K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$27K |
| 4 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$11.7K |
| 5 |
GI
GAMMA Investing
Foster City,
California
|
-$2.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $72K | +$150K | +196 | +2,450% |
|
|
TSS
2
Two Sigma Securities
New York
| $9.19K | +$7.66K | +10 | +63% |
|
|
3
Morgan Stanley
New York
| $4.04K | +$8.43K | +11 | New |
|
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $1.7K | +$2.3K | +3 | +150% |
|
|
CIM
5
Contravisory Investment Management
Norwell,
Massachusetts
| $282 | – | – | – |
|
|
GI
6
GAMMA Investing
Foster City,
California
| $81 | -$2.3K | -3 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$32K | -29 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$30K | -27 | Closed |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$27K | -24 | Closed |
|
|
GSC
10
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$11.7K | -10 | Closed |
|
11
Bank of America
Charlotte,
North Carolina
| – | -$769 | -1 | Closed |
|
|
HT
12
Headlands Technologies
Chicago,
Illinois
| – | -$7 | – | – |
|
|
IC
13
Innealta Capital
Austin,
Texas
| – | -$11 | – | – |
|
BDRX Hedge Fund Activity: Q3 2024 in Review
5 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q3 2024, worth a combined $87.3K — down 36% from $136K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BDRX and 1 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, adding an estimated $150K. The largest seller was Virtu Financial, exiting entirely with an estimated $32K sold.
- 5 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q3 2024, down from 10 in Q2 2024.
- Funds reported $87.3K of Biodexa Pharmaceuticals stock for Q3 2024, down 36% quarter-over-quarter.
- 1 fund opened new Biodexa Pharmaceuticals positions in Q3 2024 and 6 closed out, a net change of -5 holders.
- The largest Biodexa Pharmaceuticals buyer in Q3 2024 was UBS Group, an estimated $150K added.
- The largest Biodexa Pharmaceuticals seller in Q3 2024 was Virtu Financial, an estimated $32K sold.
Based on aggregated 13F filings for Q3 2024.